Neurocrine Biosciences, Inc. (NASDAQ:NBIX) – Stock analysts at Leerink Swann boosted their FY2017 earnings estimates for Neurocrine Biosciences in a research note issued on Wednesday, Zacks Investment Research reports. Leerink Swann analyst P. Matteis now expects that the company will post earnings per share of ($1.67) for the year, up from their previous estimate of ($2.48). Leerink Swann currently has a “Outperform” rating and a $83.00 target price on the stock. Leerink Swann also issued estimates for Neurocrine Biosciences’ Q4 2017 earnings at $0.03 EPS, Q1 2018 earnings at ($0.30) EPS, Q2 2018 earnings at ($0.29) EPS, Q3 2018 earnings at ($0.04) EPS, Q4 2018 earnings at ($0.19) EPS, FY2018 earnings at ($0.83) EPS and FY2019 earnings at $1.05 EPS.
Neurocrine Biosciences (NASDAQ:NBIX) last issued its quarterly earnings results on Wednesday, November 1st. The company reported ($0.13) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.49) by $0.36. The firm had revenue of $60.77 million during the quarter, compared to analyst estimates of $29.38 million. During the same quarter last year, the firm posted ($0.43) EPS.
ILLEGAL ACTIVITY NOTICE: “FY2017 EPS Estimates for Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Lifted by Leerink Swann” was originally posted by Week Herald and is the property of of Week Herald. If you are reading this story on another website, it was illegally stolen and republished in violation of US and international copyright laws. The legal version of this story can be accessed at https://weekherald.com/2017/11/15/fy2017-eps-estimates-for-neurocrine-biosciences-inc-nbix-boosted-by-leerink-swann.html.
A number of other research analysts also recently issued reports on NBIX. BMO Capital Markets boosted their price target on shares of Neurocrine Biosciences from $75.00 to $84.00 and gave the stock an “outperform” rating in a research report on Friday, August 4th. Cowen and Company restated an “outperform” rating and issued a $65.00 price target (up previously from $60.00) on shares of Neurocrine Biosciences in a research report on Wednesday, August 9th. BidaskClub upgraded shares of Neurocrine Biosciences from a “hold” rating to a “buy” rating in a research report on Wednesday, August 9th. Piper Jaffray Companies set a $68.00 price target on shares of Neurocrine Biosciences and gave the stock a “buy” rating in a research report on Thursday, August 24th. Finally, ValuEngine upgraded shares of Neurocrine Biosciences from a “sell” rating to a “hold” rating in a research report on Friday, September 1st. One investment analyst has rated the stock with a hold rating and eighteen have given a buy rating to the company. Neurocrine Biosciences has a consensus rating of “Buy” and an average price target of $78.88.
Neurocrine Biosciences (NASDAQ NBIX) opened at $74.17 on Monday. Neurocrine Biosciences has a 1 year low of $37.35 and a 1 year high of $75.98. The company has a debt-to-equity ratio of 1.05, a quick ratio of 14.37 and a current ratio of 14.38.
In other Neurocrine Biosciences news, insider Christopher Flint Obrien sold 6,925 shares of the company’s stock in a transaction on Monday, October 2nd. The shares were sold at an average price of $61.04, for a total transaction of $422,702.00. Following the transaction, the insider now owns 55,898 shares in the company, valued at $3,412,013.92. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Haig P. Bozigian sold 26,250 shares of the company’s stock in a transaction on Wednesday, September 6th. The stock was sold at an average price of $60.00, for a total transaction of $1,575,000.00. Following the transaction, the insider now owns 144,601 shares in the company, valued at approximately $8,676,060. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 140,810 shares of company stock worth $9,035,398. Corporate insiders own 4.80% of the company’s stock.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in NBIX. Janus Henderson Group PLC acquired a new position in Neurocrine Biosciences during the second quarter worth $246,888,000. BlackRock Inc. grew its stake in shares of Neurocrine Biosciences by 14,216.0% in the 1st quarter. BlackRock Inc. now owns 5,031,933 shares of the company’s stock worth $217,884,000 after acquiring an additional 4,996,784 shares in the last quarter. TimesSquare Capital Management LLC grew its stake in shares of Neurocrine Biosciences by 299.4% in the 2nd quarter. TimesSquare Capital Management LLC now owns 2,315,373 shares of the company’s stock worth $106,507,000 after acquiring an additional 1,735,700 shares in the last quarter. HealthCor Management L.P. grew its stake in shares of Neurocrine Biosciences by 108.2% in the 2nd quarter. HealthCor Management L.P. now owns 2,550,178 shares of the company’s stock worth $117,308,000 after acquiring an additional 1,325,178 shares in the last quarter. Finally, Perceptive Advisors LLC grew its stake in shares of Neurocrine Biosciences by 33.9% in the 3rd quarter. Perceptive Advisors LLC now owns 4,791,589 shares of the company’s stock worth $293,629,000 after acquiring an additional 1,214,000 shares in the last quarter.
About Neurocrine Biosciences
Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Neurocrine Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.